D's third-quarter earnings are better than expected. It plans to invest $43 billion in the next five years.

PCAR reports better-than-expected Q3 earnings and expects capex and R&D expenses for 2024 in the band of $760-$800 million and $450-$470 million,...

ZION's third-quarter 2024 results beat estimates driven by higher NII and lower provisions. Yet, high adjusted expenses and lower non-interest income...

MTZ's third-quarter results benefit from strength in the diversified business model and strong bookings of renewable energy projects.

PWR's third-quarter results benefit from strength in the Electric Power and Renewable Energy segments.

On BNTX's third-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its oncology pipeline.

Weakness in both segments weighs on SWK's top line in the third quarter of 2024.

UTHR reports better-than-expected results in third-quarter 2024 on the back of strong demand for its treprostinil medications, especially Tyvaso.

NOV expects a 3-5% year-over-year revenue decline in Q4 2024. Adjusted EBITDA is anticipated to be between $280 million and $300 million for the same...

CI's strong third-quarter results benefit from a strong Evernorth Health Services segment. Higher expenses partially offset the positives.